-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MET-5 in Hypertriglyceridemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MET-5 in Hypertriglyceridemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MET-5 in Hypertriglyceridemia Drug Details: MET-5 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LY-3857210 in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LY-3857210 in Osteoarthritis Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LY-3857210 in Osteoarthritis Pain Drug Details: LY-3857210 under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MET-2 in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MET-2 in Major Depressive Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MET-2 in Major Depressive Disorder Drug Details: MET-2 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mirvetuximab Soravtansine in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mirvetuximab Soravtansine in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mirvetuximab Soravtansine in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
Generalized Anxiety Disorder (GAD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Generalized Anxiety Disorder (GAD) - Drugs In Development, 2023’, provides an overview of the Generalized Anxiety Disorder (GAD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Generalized Anxiety Disorder (GAD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hypopharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypopharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Hypopharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Malignant Pleural Mesothelioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Pleural Mesothelioma - Drugs In Development, 2023’, provides an overview of the Malignant Pleural Mesothelioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Oropharyngeal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Oropharyngeal Cancer - Drugs In Development, 2023’, provides an overview of the Oropharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...